We need your mantras for a new project! Share with us.
We are aware of and actively working on an issue where the first page/opening posts of threads with more than one page are not able to be accessed. We hope to have this resolved soon. Thank you for your patience!
Lynparza Approved To Treat High-Risk, Early-Stage, HER2-, BRCA+
moderators
Posts: 10,281
Lynparza Approved To Treat High-Risk, Early-Stage, HER2-Negative Breast Cancer With BRCA Mutation
Mar 13, 2022
The FDA approved Lynparza to treat early-stage, HER2-negative breast cancer with a BRCA1 or BRCA2 mutation and a high risk of recurrence, which also has been previously treated with chemotherapy — either before or after surgery. Read more...
0
Categories
Join Us on Zoom: Upcoming virtual support groups. Read more...
Share more about you! Fill out your profile.